Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001222156 | SCV001394243 | pathogenic | not provided | 2025-01-21 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Val101Glufs*10) in the MSH3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH3 are known to be pathogenic (PMID: 27476653, 37402566). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with MSH3-related conditions. ClinVar contains an entry for this variant (Variation ID: 950444). For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV002436860 | SCV002753074 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-02-09 | criteria provided, single submitter | clinical testing | The c.302_306delTAAAG pathogenic mutation, located in coding exon 2 of the MSH3 gene, results from a deletion of 5 nucleotides at nucleotide positions 302 to 306, causing a translational frameshift with a predicted alternate stop codon (p.V101Efs*10). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Myriad Genetics, |
RCV003458647 | SCV004189201 | pathogenic | Familial adenomatous polyposis 4 | 2023-08-29 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |